Close

Drug Research

Thermo Fisher Scientific Extends SARS-CoV-2 GlobalAccess Sequencing Program to Support Research on New Virus Strains

As scientists continue to identify new strains of the SARS-CoV-2 virus, including the B.1.1.7 UK variant that studies suggest is more transmissible, genetic sequencing is being used to track these strains and new ones that are emerging, as well...

Lonza to Partner with Capricor Therapeutics for the Development of Duchenne Muscular Dystrophy Cell Therapy

Lonza and Capricor Therapeutics, a US-based clinical-stage biotechnology company, announced on Jan. 12, 2020 that they are entering into an agreement for the development of CAP-1002, Capricor's clinical cell therapy that uses allogeneic cardiosphere-derived cells technology for the treatment...

US FDA grants emergency use authorization to Quanterixs Simoa SARS-CoV-2 N protein antigen test

Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its Simoa SARS-CoV-2 N Protein Antigen Test that can...

Abzena announces opening of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors

Abzena, a Global Partner Research Organization for integrated bench to market solutions for biologics and bioconjugates, has announced the addition of a 6th Global site that will augment cGMP manufacturing capacity for mammalian biologics. This expansion is driven by...

Baxter BioPharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

Baxter International Inc., a global leader in sterile medication production and delivery, announced that Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M™ adjuvant. Baxter...

FUJIFILM Diosynth Biotechnologies Begins Production of Two COVID-19 Vaccines Candidates at Texas Facility

FUJIFILM Diosynth Biotechnologies and the Texas A&M University System Center for Innovation in Advanced Development & Manufacturing (CIADM) announced that production has begun in Texas on two different COVID-19 vaccine candidates with support from the U.S. government to meet...

CEVEC Pharma grants Biogen rights to its proprietary Elevecta Technology for manufacturing of gene therapy products

CEVEC Pharmaceuticals GmbH announced the signing of a license agreement with Biogen Inc. for the use of CEVEC’s proprietary ELEVECTA® Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Under the terms of the agreement, CEVEC...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read